cook's contribution, page-6

Tooluck,

Thank you for the correction. Tamiflu sales was for 2 financial quarter. Let us update the market share calculations:

Relenza sales in the last 2 quarters = (9 + 12 ) million Pound = 27.65 million CHF
Tamiflu sales = $ 262 million CHF
Therefore market share = 27.65 / (27.65+262) = 9.5%

Relenza is a superior antiviral to Tamiflu and with the flu virus increasing resistance to Tamiflu, the 9.5% market share hardly a reflection of an enthusiatic GSK. Your employee Cook had been rewarded for the great GSK settlement. Why should he not be accountable after he had claimed the reward of half a million of free oopies when the basis of his reward is proven to be a disaster?

Remember Cook and the board turned down the $100 million settlement offer + reimbursement for legal cost - an offer worth about $130million and Cook told shareholders $20 million is a good settlement upon which he was rewarded the free oopies.